Article thumbnail

Patients' outcome according to <i>KRAS-BRAF</i> mutations status <i>and AREG or EREG</i> mRNA expression.

By Zacharenia Saridaki (357374), Maria Tzardi (357376), Chara Papadaki (269416), Maria Sfakianaki (357378), Fraga Pega (357380), Aristea Kalikaki (357382), Eleftheria Tsakalaki (357383), Maria Trypaki (269427), Ippokratis Messaritakis (357384), Efstathios Stathopoulos (357386), Dimitris Mavroudis (74460), Vassilis Georgoulias (74459) and John Souglakos (74461)

Abstract

<p><b>Panel</b> A: Time to Tumor Progression (TTP) according to <i>KRAS-BRAF</i> mutations status and <i>AREG</i> mRNA expression. Panel B: Median Overall Survival (OS) according to <i>KRAS-BRAF</i> mutations status and <i>AREG</i> mRNA expression. Panel C: Time to Tumor Progression (TTP) according to <i>KRAS-BRAF</i> mutations status and <i>EREG</i> mRNA. Panel D Median Overall Survival (OS) according to <i>KRAS-BRAF</i> mutations status and <i>EREG</i> mRNA.</p

Topics: Pharmacology, Developmental Biology, Cancer, mutations, areg, mrna
Year: 2013
DOI identifier: 10.1371/journal.pone.0015980.g008
OAI identifier: oai:figshare.com:article/476314
Provided by: FigShare
Download PDF:
Sorry, we are unable to provide the full text but you may find it at the following location(s):
  • https://figshare.com/articles/... (external link)
  • Suggested articles


    To submit an update or takedown request for this paper, please submit an Update/Correction/Removal Request.